3
|
Zhou H, Mondragón L, Xie W, Mauseth B, Leduc M, Sauvat A, Gomes-da-Silva LC, Forveille S, Iribarren K, Souquere S, Bezu L, Liu P, Zhao L, Zitvogel L, Sveinbjørnsson B, Eksteen JJ, Rekdal Ø, Kepp O, Kroemer G. Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals. Cell Death Dis 2018; 9:1086. [PMID: 30352991 PMCID: PMC6199251 DOI: 10.1038/s41419-018-1127-3] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2018] [Revised: 09/28/2018] [Accepted: 10/01/2018] [Indexed: 02/08/2023]
Abstract
Oncolytic peptides and peptidomimetics are being optimized for the treatment of cancer by selecting agents with high cytotoxic potential to kill a maximum of tumor cells as well as the capacity to trigger anticancer immune responses and hence to achieve long-term effects beyond therapeutic discontinuation. Here, we report on the characterization of two novel oncolytic peptides, DTT-205 and DTT-304 that both selectively enrich in the lysosomal compartment of cancer cells yet differ to some extent in their cytotoxic mode of action. While DTT-304 can trigger the aggregation of RIP3 in ripoptosomes, coupled to the phosphorylation of MLKL by RIP3, DTT-205 fails to activate RIP3. Accordingly, knockout of either RIP3 or MLKL caused partial resistance against cell killing by DTT-304 but not DTT-205. In contrast, both agents shared common features in other aspects of pro-death signaling in the sense that their cytotoxic effects were strongly inhibited by both serum and antioxidants, partially reduced by lysosomal inhibition with bafilomycin A1 or double knockout of Bax and Bak, yet totally refractory to caspase inhibition. Both DTT-304 and DTT-205 caused the exposure of calreticulin at the cell surface, as well as the release of HMGB1 from the cells. Mice bearing established subcutaneous cancers could be cured by local injection of DTT-205 or DTT-304, and this effect depended on T lymphocytes, as it led to the establishment of a long-term memory response against tumor-associated antigens. Thus, mice that had been cured from cancer by the administration of DTT compounds were refractory against rechallenge with the same cancer type several months after the disappearance of the primary lesion. In summary, DTT-205 and DTT-304 both have the capacity to induce immunotherapeutic oncolysis.
Collapse
Affiliation(s)
- Heng Zhou
- Metabolomics and Cell Biology Platforms, Gustave Roussy Comrehensive Cancer Institute, Villejuif, France.,Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U, 1138, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Université Pierre et Marie Curie, Paris, France.,Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
| | - Laura Mondragón
- Metabolomics and Cell Biology Platforms, Gustave Roussy Comrehensive Cancer Institute, Villejuif, France.,Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U, 1138, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Université Pierre et Marie Curie, Paris, France
| | - Wei Xie
- Metabolomics and Cell Biology Platforms, Gustave Roussy Comrehensive Cancer Institute, Villejuif, France.,Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U, 1138, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Université Pierre et Marie Curie, Paris, France
| | - Brynjar Mauseth
- Lytix Biopharma, Oslo, Norway.,Division of Cancer, Surgery and Transplantation, Oslo University Hospital, Rikshospitalet, Oslo, Norway.,Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Marion Leduc
- Metabolomics and Cell Biology Platforms, Gustave Roussy Comrehensive Cancer Institute, Villejuif, France.,Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U, 1138, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Université Pierre et Marie Curie, Paris, France
| | - Allan Sauvat
- Metabolomics and Cell Biology Platforms, Gustave Roussy Comrehensive Cancer Institute, Villejuif, France.,Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U, 1138, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Université Pierre et Marie Curie, Paris, France
| | - Lígia C Gomes-da-Silva
- Metabolomics and Cell Biology Platforms, Gustave Roussy Comrehensive Cancer Institute, Villejuif, France.,Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U, 1138, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Université Pierre et Marie Curie, Paris, France.,Chemistry Department, University of Coimbra, Coimbra, Portugal
| | - Sabrina Forveille
- Metabolomics and Cell Biology Platforms, Gustave Roussy Comrehensive Cancer Institute, Villejuif, France.,Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U, 1138, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Université Pierre et Marie Curie, Paris, France
| | - Kristina Iribarren
- Metabolomics and Cell Biology Platforms, Gustave Roussy Comrehensive Cancer Institute, Villejuif, France.,Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U, 1138, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Université Pierre et Marie Curie, Paris, France
| | - Sylvie Souquere
- Gustave Roussy Comprehensive Cancer Center, Villejuif, France.,CNRS, UMR9196, Villejuif, France
| | - Lucillia Bezu
- Metabolomics and Cell Biology Platforms, Gustave Roussy Comrehensive Cancer Institute, Villejuif, France.,Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U, 1138, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Université Pierre et Marie Curie, Paris, France
| | - Peng Liu
- Metabolomics and Cell Biology Platforms, Gustave Roussy Comrehensive Cancer Institute, Villejuif, France.,Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U, 1138, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Université Pierre et Marie Curie, Paris, France
| | - Liwei Zhao
- Metabolomics and Cell Biology Platforms, Gustave Roussy Comrehensive Cancer Institute, Villejuif, France.,Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U, 1138, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Université Pierre et Marie Curie, Paris, France
| | - Laurence Zitvogel
- Gustave Roussy Comprehensive Cancer Center, Villejuif, France.,University of Paris Sud XI, Kremlin Bicêtre, France.,Institut National de la Santé et de la Recherche Medicale (INSERM), U1015, Villejuif, France.,Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France
| | - Baldur Sveinbjørnsson
- Lytix Biopharma, Oslo, Norway.,Institute of Medical Biology, University of Tromsø, Tromsø, Norway.,Karolinska Institutet, Department of Women's and Children's Health, Stockholm, Sweden
| | - J Johannes Eksteen
- Norut Northern Research Institute, SIVA Innovation Centre, Tromsø, Norway
| | - Øystein Rekdal
- Lytix Biopharma, Oslo, Norway.,Institute of Medical Biology, University of Tromsø, Tromsø, Norway
| | - Oliver Kepp
- Metabolomics and Cell Biology Platforms, Gustave Roussy Comrehensive Cancer Institute, Villejuif, France. .,Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U, 1138, Paris, France. .,Université Paris Descartes, Sorbonne Paris Cité, Paris, France. .,Université Pierre et Marie Curie, Paris, France.
| | - Guido Kroemer
- Metabolomics and Cell Biology Platforms, Gustave Roussy Comrehensive Cancer Institute, Villejuif, France. .,Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U, 1138, Paris, France. .,Université Paris Descartes, Sorbonne Paris Cité, Paris, France. .,Université Pierre et Marie Curie, Paris, France. .,Karolinska Institutet, Department of Women's and Children's Health, Stockholm, Sweden. .,Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
| |
Collapse
|